Purpose

The purpose of this study is to collect blood specimens from individuals post infection or post vaccination over time to assess COVID19 Immunity.

Condition

Eligibility

Eligible Ages
Over 13 Years
Eligible Genders
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Males and females ≥13 years old. - Not vaccinated and were previously positive for COVID-19 OR are vaccinated for COVID-19. - Provides test report to demonstrate prior COVID-19 positive result (only applicable to unvaccinated subjects who were previously positive for COVID-19, not applicable for COVID-19 vaccinated subjects). - Provides informed consent and completed questionnaire. - Able to register the collection kit on the DxTerity portal. - Able to collect and ship blood samples back to DxTerity.

Exclusion Criteria

  • Unable to provide COVID-19 positive test report (only applicable to unvaccinated subjects who were previously positive for COVID-19, not applicable for COVID-19 vaccinated subjects). - Unable to complete informed consent and/or questionnaire. - Unable to complete the study activities in a timely manner.

Study Design

Phase
Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Arm Groups

ArmDescriptionAssigned Intervention
COVID-19 Vaccinated Individuals Males and females, 13years old and above, vaccinated for COVID-19
Previously positive for COVID-19 and unvaccinated individuals Males and females, 13years old and above, unvaccinated for COVID-19 and previously tested positive for COVID-19.
No previous COVID infection or vaccination Males and females, 13years old and above, unvaccinated for COVID-19 and previously not tested positive for COVID-19.

Recruiting Locations

More Details

NCT ID
NCT05080231
Status
Completed
Sponsor
DxTerity Diagnostics

Detailed Description

The DxTerity COVID-19 Immunity Assessment Collection Mailer Kit contains the DxCollect MicroCollection Device (MCD) Serology fingerstick blood collection device packaged as a home collection kit, designed for collection and shipment of fingerstick blood back to DxTerity CLIA (Clinical Laboratory Improvements Amendment) certified laboratory for testing. The clinical performance of the collection device for use with anti-SARS-CoV-2 antibody tests will be evaluated for use with cPASS™ anti-SARS-CoV-2 neutralizing antibody detection kit (EUA 201427). The samples may also be used for assessing immunity or protection post COVID-19 vaccination.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.